BCRXBioCryst Pharmaceuticals, Inc.
Is it safe?
Solid, nothing alarming: quality strong, but heavy debt (CCC) and big price swings.
Some accounting flags, worth a closer look Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
High fundamental quality Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -84% · now 31% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can BCRX take a bad year?
The deepest fall in BCRX's price history on file is −84%; it is 31% below its high today.
Worst drawdown on file · −31% today
- Interest cover
- none
Interest cover · no operating profit to pay the interest bill from
- Annualised volatility
- 51%
Annualised volatility · S&P 500 16% · about 3 times the market's own swing
Details›
- Cash and short-term investments
- $353M
- EBITDA, trailing twelve months
- −$311M
- Operating profit, trailing twelve months
- −$313M
- Annualised volatilitytwo years of daily moves
- 51%
- Worst drawdown on file
- −84%
- Below its 52-week high
- 31%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.
Drug Manufacturers, Specialty & Generic
Ranks #34 of 39 by RyuScore